Johnson & Johnson: Johnson & Johnson's TAR-200 for Bladder Cancer Shows High Rates of Disease-Free Survival, Bladder Preservation

Early findings from Johnson & Johnson's Phase IIb SunRISe-1 trial show the promise of TAR-200 in patients with Bacillus Calmette-Guérin-unresponsive, high-risk non-muscle-invasive bladder cancer, highlighting its potential as a non-surgical treatment alternative.